Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Clinicopathologic characteristics of isthmic papillary thyroid microcarcinoma patientsCharacteristicTotal (n = 201)Sex Male, n (%)62 (30.8%) Female, n (%)139 (69.2%)Age, years, mean ± SD (range)43.35 ± 11.94( 21 to 77) <55 year160 (79.6%) ≥55 year41 (20.4%)Tumor size, cm, mean ± SD (range)0.59 ± 0.20(0.3-1.0) ≤5 mm, n (%)94 (46.8%) >5 mm, n (%)107 (53.2%)CLNM, n (%) Yes61 (30.3%) No140 (69.7%)mETE, n (%) Yes114 (56.7%) No87 (43.3%) Mean no. dissected CLN6.99 ± 4.50 Mean no. metastatic CLN0.94 ± 1.93 Ratio of CLNM0.13 ± 0.23 Maximal size of metastatic foci (mm), mean ± SD1.36 ± 1.10 Metastatic foci ≥ 2 mm, n (%)17/61 (27.9%) BRAFV600E mutation, n (%)150 (74.6%)Hoarseness n (%)0 (0%) Hypocalcemia Transient n (%)0 (0%) Permanent* n (%)0 (0%) Recurrence, n (%)9 (4.5%) Follow-up time, months, mean(range)30.7 ± 11.9(12 to 88)CLN, central lymph node; mETE, Microscopic Extrathyroidal Extension; CLNM, Central Lymph Node Metastasis*: Permanent hypocalcemia was defined as persistently decreased serum calcium levels requiring ongoing calcium supplementation and calcitriol therapy for more than 6 months after surgery
Source: Demographic and tumor characteristics. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Patients were classified into two subgroups according to tumor size: isthmic PTMC ≤ 5 mm (n = 94) and isthmic PTMC > 5 mm (n = 107).
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Isthmic papillary thyroid microcarcinoma: clinicopathological features and prognostic factors following isthmusectomy based on tumor size stratification
Study design awaiting verification · Discover Oncology · 2026
Original publication title
Isthmic papillary thyroid microcarcinoma: clinicopathological features and prognostic factors following isthmusectomy based on tumor size stratification
© The Author(s) 2026
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
This study aimed to compare clinicopathological features and recurrence risk in clinically node-negative (cN0) solitary isthmic papillary thyroid microcarcinoma (PTMC) ≤ 5 mm and > 5 mm in diameter treated with isthmusectomy, and to identify predictors of recurrence.
Source: BackgroundAbstract: What methods does the paper describe?
A retrospective review was performed of 201 cN0 patients with solitary isthmic PTMC who underwent isthmusectomy between 2018 and 2024. Patients with preoperative high-risk features were excluded. Subgroup analysis compared clinicopathological characteristics between the ≤ 5 mm (n = 107) and > 5 mm (n = 94) groups. Univariate and multivariate Cox models were used to identify factors associated with recurrence-free survival (RFS).
Source: MethodsAbstract: Results
Significant differences were observed between the two groups in tumor size (p < 0.001), central lymph node metastasis (CLNM) (p = 0.009), microscopic extrathyroidal extension(mETE) (p < 0.001), and BRAFV600E mutation (p = 0.008). During follow-up, 9 patients (4.5%) developed recurrence. Recurrence was significantly associated with tumor size > 5 mm (p = 0.028), CLNM (p = 0.002), and a higher number of metastatic central lymph node (CLN) (p < 0.001). Receiver operating characteristic analysis identified metastatic CLNs > 3 as the optimal cut-off for predicting recurrence.
Kaplan: Meier analysis demonstrated worse RFS in patients with tumors > 5 mm (p = 0.031). Multivariate analysis confirmed metastatic CLNs > 3 as an independent predictor of recurrence (HR 5.298, 95% CI 1.473 to 19.060, p < 0.001).
Source: ResultsAbstract: Conclusion
This study demonstrated that isthmic PTMC tumors > 5 mm were associated with a higher risk of recurrence. In addition, CLNM, especially a metastatic CLNs > 3, may have prognostic significance and should be considered in surgical decision-making for isthmic PTMC.
Source: ConclusionAuthors’ abstract
Background
This study aimed to compare clinicopathological features and recurrence risk in clinically node-negative (cN0) solitary isthmic papillary thyroid microcarcinoma (PTMC) ≤ 5 mm and > 5 mm in diameter treated with isthmusectomy, and to identify predictors of recurrence.
Methods
A retrospective review was performed of 201 cN0 patients with solitary isthmic PTMC who underwent isthmusectomy between 2018 and 2024. Patients with preoperative high-risk features were excluded. Subgroup analysis compared clinicopathological characteristics between the ≤ 5 mm (n = 107) and > 5 mm (n = 94) groups. Univariate and multivariate Cox models were used to identify factors associated with recurrence-free survival (RFS).
Results
Significant differences were observed between the two groups in tumor size (p < 0.001), central lymph node metastasis (CLNM) (p = 0.009), microscopic extrathyroidal extension(mETE) (p < 0.001), and BRAFV600E mutation (p = 0.008). During follow-up, 9 patients (4.5%) developed recurrence. Recurrence was significantly associated with tumor size > 5 mm (p = 0.028), CLNM (p = 0.002), and a higher number of metastatic central lymph node (CLN) (p < 0.001). Receiver operating characteristic analysis identified metastatic CLNs > 3 as the optimal cut-off for predicting recurrence.
Kaplan: Meier analysis demonstrated worse RFS in patients with tumors > 5 mm (p = 0.031). Multivariate analysis confirmed metastatic CLNs > 3 as an independent predictor of recurrence (HR 5.298, 95% CI 1.473 to 19.060, p < 0.001).
Conclusion
This study demonstrated that isthmic PTMC tumors > 5 mm were associated with a higher risk of recurrence. In addition, CLNM, especially a metastatic CLNs > 3, may have prognostic significance and should be considered in surgical decision-making for isthmic PTMC.
Publication and source details
Original title: Isthmic papillary thyroid microcarcinoma: clinicopathological features and prognostic factors following isthmusectomy based on tumor size stratification
Feng Zhu; CuiWei Li; YiBin Shen; MengXia Li; XueYu Zhou; YiJun Wu
Discover Oncology · 2026
© The Author(s) 20262026https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Zhejiang medical science and technology projects2022KY786Zhu FengRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-10T23:29:53.612520+00:00
DOI: 10.1007/s12672-026-04950-0 · PMC13199557